Test of an HPV vaccine-like treatment for HPV16 in women
Part of Infections clinical trials.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–49
- You have HPV16 infection confirmed by two positive HPV tests at least 3 months apart
- Your cervical screening results are not cancer or high-grade changes (acceptable results include NILM, ASC-US, LSIL, or CIN1)
- Your colposcopy exam (looking closely at the cervix with a special camera) is satisfactory
- Pregnancy test is negative, and you will use reliable birth control during the study
- Your blood, kidney, liver tests, and ECG (heart tracing) are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.